Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

2022240 citationsJournal Articlebronze Open Access

Authors

Stuart J. Connolly · Jimma University

Ganesan Karthikeyan · Jimma University

Mpiko Ntsekhe · Jimma University

Abraham Haileamlak · Jimma University

Ahmed El Sayed · Jimma University

Alaa El Ghamrawy · Jimma University

Albertino Damasceno · Jimma University

Abstract

Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 11, pp. 978-988

DOI: 10.1056/nejmoa2209051

Field-Weighted Citation Impact: 36.93